Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Vanda Pharmaceuticals Inc.

Get SEC filing alerts via email and in your feed for Vanda Pharmaceuticals Inc.

VNDA

Vanda Pharmaceuticals Inc.

About Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for high unmet medical needs. Its portfolio includes drugs for schizophrenia, bipolar disorder, sleep disorders, multiple sclerosis, and rare autoinflammatory diseases. The company leverages genetics and genomics in drug discovery, partners strategically, and advances products through clinical trials and regulatory approval to serve global markets.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Vanda Pharmaceuticals Inc.

1
1
Vanda Pharmaceuticals Inc. Vanda Pharmaceuticals Reports $51.7 Million Revenue in Q1 2026, Net Loss of $48.6 Million

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
Vanda Pharmaceuticals Inc. Vanda Pharmaceuticals Reports $216.1M Revenue for Fiscal Year 2025, Net Loss of $220.5M

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
Vanda Pharmaceuticals Inc. Vanda Pharmaceuticals Reports 18% Revenue Growth to $56.3 Million in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Vanda Pharmaceuticals Inc. Vanda Pharmaceuticals Reports Q2 2025 Revenue of $52.6M, Net Loss of $27.2M

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Vanda Pharmaceuticals Inc. Vanda Pharmaceuticals Reports $50M Revenue in Q1 2025, Net Loss Increases to $29.5M

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Vanda Pharmaceuticals Inc. Vanda Pharmaceuticals Reports $198.8M Revenue in Fiscal Year 2024, Net Loss of $18.9M

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
Vanda Pharmaceuticals Inc. Vanda Pharmaceuticals Reports 23% Revenue Growth, Net Loss in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments